Resultados de la búsqueda

Sanchis J, Bueno H, Martí Sánchez D, Martinez-Selles M, Díez Villanueva P, Barrabes JA, Marín F, Villa A, Sanmartin Fernandez M, Llibre C, Sionis A, Elizaga J, Alfonso F, Nuñez E, Núñez J, Kunadian V, Ariza-Solé A. Effects of routine invasive management on reinfarction risk in older adults with frailty and non-ST-segment elevation myocardial infarction: a subanalysis of a randomised clinical trial. Heart (2025) Feb 8 [Epub ahead of print]

Salinas P, Romaguera R, Gómez-Lara J, Brugaletta S, Gómez-Menchero A, Martín P, Romero M, García-Blas S, Jiménez M, Jiménez VA, Bordes P, Bayón J, Salvatella N, Alameda M, Hyun-Lee D, Trillo-Nouche R, López-Benito M, Frutos A, Moreu J, García Del Blanco B, Mohandes M, Bosa Ojeda F, Hernández Hernández F, Pinar-Bermúdez E, Jiménez-Quevedo P, Rosselló X, Pocock S, Sabaté M, Gómez-Hospital JA, Comin-Colet J, Gonzalo N, Fernández Ortiz A; SUGAR trial Investigators. Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial. Heart (2025) Jun 25 [Epub ahead of print]

Sönmez M, Stüdemann T, Manthey C, Covic A, Shehata N, Im J, Schwarzova B, Rössinger J, Srikantharajah R, Shibamiya A, Schwedhelm E, Eschenhagen T, Christ T, Weinberger F. Modulation of cardiomyocyte contractility and action potentials with chemogenetic chloride currents. J Physiol (2025) 603:1399-1415
Link to the full text in Repisalud

Gonçalves A, Alves IN, Mendes C, Miranda D, Conceição G, Almeida-Coelho J, Martins D, Miranda I, Rodrigues A, Silva C, Oliveira SM, Sereno J, Ferreira MJ, Dischinger U, Girão H, Leite-Moreira AF, Sequeira V, Falcão-Pires I. Ketogenic diet and ketone salts differentially improve cardiometabolic complications in an HFpEF rat model. J Physiol (2025) Apr 3 [Epub ahead of print]

Cabrera-Romero E, Serrao-Faria LA, Mora-Ayestarán N, Peiró-Aventín B, Espinoza A, de Castro D, Cobo-Marcos M, Domínguez F, González-López E, Garcia-Pavia P. Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy. Amyloid (2025) 32:87-89

Suhr OB, Grogan M, Silva AMD, Karam C, Garcia-Pavia P, Drachman B, Zago W, Tripuraneni R, Kinney GG. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid (2025) 32:14-21

Gómez de Cedrón M, Moreno-Rubio J, de la O Pascual V, Alvarez B, Villarino M, Sereno M, Gómez-Raposo C, Roa S, López Gómez M, Merino-Salvador M, Jiménez Gordo A, Falagán S, Aguayo C, Zambrana F, Tabarés B, Garrido B, Cruz-Gil S, Fernández Díaz CM, Fernández LP, Molina S, Crespo MC, Ouahid Y, Montoya JJ, Ramos Ruíz R, Reglero G, Ramírez de Molina A, Casado E. Randomized clinical trial in cancer patients shows immune metabolic effects exerted by formulated bioactive phenolic diterpenes with potential clinical benefits Front Immunol (2025) 16
Link to the full text in Repisalud

Gómez de Cedrón M, Moreno-Rubio J, de la O Pascual V, Alvarez B, Villarino M, Sereno M, Gómez-Raposo C, Roa S, López Gómez M, Merino-Salvador M, Jiménez-Gordo A, Falagán S, Aguayo C, Zambrana F, Tabarés B, Garrido B, Cruz-Gil S, Fernández Díaz CM, Fernández LP, Molina S, Crespo MC, Ouahid Y, Montoya JJ, Ramos Ruíz R, Reglero G, Ramírez de Molina A, Casado E. Randomized clinical trial in cancer patients shows immune metabolic effects exerted by formulated bioactive phenolic diterpenes with potential clinical benefits. Front Immunol (2025) 16:1519978
Link to the full text in Repisalud

Davis BJ, Volk H, Nguyen O, Kamna D, Chen H, Barriales-Villa R, Garcia-Pavia P, Olivotto I, Owens AT, Coats CJ, Abraham TP, Solomon SD, Maron MS, Masri A. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy J Am Heart Assoc (2025) 14:e038758
Link to the full text in Repisalud

Feil S, Zaldivia MTK, Kiesel J, Roessing M, Peter A, Morales-Cano D, Bentzon JF, Lehners M, Feil R. Smooth Muscle Cell-Derived Fibronectin Promotes an Atheroprotective Smooth Muscle Cell Phenotype Associated With Altered NO-cGMP Signaling. J Am Heart Assoc (2025) 14:e040395